araag2/HINT huggingface dataset:
Clinical trial NCT01364428 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (diagnosed clinically) for minimum 24 weeks prior to randomisation
             (visit 2)

          -  Current treatment with basal-only insulin (no prandial insulin) consisting of either
             insulin detemir once daily (OD), insulin glargine OD or neutral protamine hagedorn
             (NPH) insulin OD/twice daily (BID) for at least 12 weeks prior to randomisation (visit
             2), in combination with stable doses of OAD(s) (metformin, insulin secretagogue
             (sulfonylurea or glinide), alpha-glucosidase inhibitor, pioglitazone or dipeptidyl
             peptidase IV (DPP-IV) inhibitor in any approved (according to label) dose or
             combination. Stable OAD doses are defined as unchanged doses for at least 12 weeks
             prior to randomisation (visit 2)

          -  HbA1c (glycosylated haemoglobin) between 7.0-10.0% (both inclusive) by central
             laboratory analysis

          -  Body mass index (BMI) below or equal to 45 kg/m^2

          -  Ability and willingness to adhere to the protocol including self-measured plasma
             glucose (SMPG) according to the protocol

        Exclusion Criteria:

          -  Treatment with rosiglitazone within the last 12 weeks prior to randomisation (visit 2)

          -  Treatment with glucagon like peptide-1 (GLP-1) receptor agonists within the last 12
             weeks prior to randomisation (visit 2)

          -  Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the
             last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial
             physician)

          -  Previous participation in this trial. Participation is defined as randomised.
             Re-screening is allowed once during the recruitment period

          -  Known or suspected hypersensitivity to trial products or related products

          -  The receipt of any investigational drug within 4 weeks prior to randomisation (visit
             2)
Clinical trial NCT00351910 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine, amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12, CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12, [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 to 65 years

          -  A documented diagnosis of major depressive disorder

        Exclusion Criteria:

          -  Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment

          -  Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the
             patient's current psychiatric status

          -  Patients whose current episode of depression exceeds 12 months or is less than 4 weeks
             prior to enrolment
Clinical trial NCT01998880 (phase 3, status: completed)
Conditions: lymphocytic leukemia, chronic
ICD codes: C91.11, C91.12, C91.10
Drugs: obinutuzumab, rituximab, chlorambucil
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Adults >/=18 years

          -  Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic
             Lymphoma (B-CLL)

          -  Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according
             to the National Cancer Institute (NCI) criteria

          -  Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70
             ml/min

        Exclusion Criteria:

          -  Prior CLL therapy

          -  Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's
             transformation)

          -  History of other malignancy unless the malignancy has been in remission without
             treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the
             cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate
             cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy
             alone

          -  Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus
             (HTLV) testing

          -  Patients with active infection requiring systemic treatment
Clinical trial NCT00237523 (phase 3, status: unknown status)
Conditions: fibrocystic disease of breast, fibrocystic changes of breast, fibrocystic mastopathy, pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: iogen (molecular iodine)
SMILES: II
Eligibility criteria:

        Inclusion Criteria:

          -  History of clinical breast pain.

          -  Documentation of 6 or more sequential days of moderate or severe pain by patient daily
             diary.

          -  Conservative measures such as local heat, non-prescription analgesics, and properly
             fitted garments are not effective for the treatment of symptoms

          -  Euthyroid with no prior history of thyroid disease.

          -  Premenopausal female between the ages of 18 and 50.

          -  The presence of at least one palpable structure (nodules, cysts) and involvement
             (diffuse nodularity or breast thickening) of at least 25% of at least one breast
             surface.

        Exclusion Criteria:

          -  History of thyroid disease

          -  Non-cyclic breast pain

          -  Treatment with gonadotropin releasing hormone (GnRH) agonist, Danocrine, tamoxifen,
             raloxifene, or bromocriptine within three months of starting the trial

          -  Initiation or change of any hormonal therapy within 6 months of enrollment; including
             birth control pills, hormone replacement therapy, any progestin including Norplant or
             Depo-Provera;

          -  Current treatment with iodine or iodine-containing medications or diagnostics

          -  Known hypersensitivity to iodine-containing products

          -  Breast implants;

          -  Oophorectomy (complete or partial)

          -  Uncontrolled hypertension;

          -  Breast biopsy breast biopsy within two months of screening; or expectation of a breast
             biopsy during the study for a suspicious mass present at baseline;

          -  Pregnant women or nursing mothers

          -  History of malignancy within the previous 5 years other than basal cell or squamous
             cell carcinoma of the skin

          -  History of breast cancer
Clinical trial NCT00410202 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: entecavir, tenofovir, adefovir, lamivudine
SMILES: CCOC(=O)C1=CC=C(N)C=C1, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Evidence of lamivudine (LVD) resistance

          -  Subjects must have a history of previous LVD treatment at screening, and must have
             evidence of at least 1 LVD resistance substitution (valine, isoleucine, or serine) at
             reverse transcriptase codon 204 (M204V/I/S)

          -  Nucleoside- and nucleotide-naive, except for LVD, and had chronic hepatitis B (HBV)
             infection

          -  Compensated liver function and must have met ALL of the following
             criteria:International normalization ratio (INR) ≤ 1.5; Serum albumin ≥ 3 g/dL (≥ 30
             g/L); Serum total bilirubin ≤ 2.5 mg/dL (≤ 42.75 μmol/L)

          -  HBV DNA > 1.72 x 10*4* IU/mL (approximately 10*5* copies/mL)

          -  Documentation of hepatitis B e antigen (HBeAg) positive and hepatitis B e antibody
             (HBeAb) negative status at screening

          -  alanine aminotransferase (ALT) ≤ 10 * upper limit of normal (ULN) at screening

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study (and for up to 6 weeks after the
             last dose of investigational product) in such a manner that the risk of pregnancy is
             minimized

          -  WOCBP include any female who has experienced menarche and who has not undergone
             successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral
             oophorectomy) or is not postmenopausal. Post menopausal is defined as:

          -  Women who are using oral contraceptives, other hormonal contraceptives (vaginal
             products, skin patches, or implanted or injectable products), or mechanical products
             such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to
             prevent pregnancy, or are practicing abstinence or where partner is sterile (e.g.,
             vasectomy), should be considered to be of child bearing potential

          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of human chorionic gonadotropin) within 72 hours prior to the
             start of investigational product

        Exclusion Criteria:

          -  Evidence of decompensated cirrhosis

          -  Coinfection with human immunodeficiency virus, hepatitis C virus , or hepatitis D
             virus

          -  Women who are pregnant or breastfeeding

          -  Sexually active fertile men not using effective birth control if their partners were
             WOCBP

          -  Laboratory values out of protocol-specified range
Clinical trial NCT00438399 (phase 3, status: completed)
Conditions: scalp psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: c. propionate - corticosteroid 1, c. propionate- corticosteroid 2, c. propionate -corticosteroid 3, corticosteroid 1- c. propionate, corticosteroid 2 - c. propionate, corticosteroid 3 - c. propionate
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects, 18 years of age or older,

          -  Subjects with moderate to severe scalp psoriasis,

          -  Subjects who signed written informed consent prior to any study procedures.

        Exclusion Criteria:

          -  Subjects who need systemic treatment for their body psoriasis,

          -  Subjects who are at risk in terms of precautions, warnings and contra-indication,

          -  Female subjects who are pregnant, nursing or planning a pregnancy during the study,

          -  Subjects with a specific washout period for topical treatment(s) on the scalp,

          -  Subjects with a specific washout period for systemic treatment(s).
Clinical trial NCT01340768 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin, sulfonylurea, metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Muslim, with type 2 diabetes mellitus

          -  Intends to fast during the month of Ramadan

          -  Hemoglobin A1c (HbA1c) ≤10% at screening

          -  On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at
             least three months, with or without metformin therapy at a stable dose

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Pregnant or breast feeding or with gestational diabetes

          -  Hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment

          -  Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)

          -  History of severe hypoglycemia (defined as a hypoglycemic event requiring the
             assistance of another individual, and/or resulting in a emergency department
             admission, physician office visit and/or hospitalization)

          -  Any use of insulin (prior to or during Ramadan)

          -  Use of any class of oral antidiabetic therapy other than an SU or metformin

          -  Current participation in another interventional study
Clinical trial NCT00479713 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ezetimibe (+) simvastatin, comparator : rosuvastatin calcium, comparator: placebo (unspecified), comparator: placebo (unspecified)
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant is currently taking a statin medication for the treatment of high
             cholesterol

          -  Participant has an LDL-C level that is greater than or equal to 100 mg/dl and less
             than or equal to 190 mg/dl

        Exclusion Criteria:

          -  Women who are pregnant or nursing, or women who intend to become pregnant

          -  Participant has any condition, situation, or is currently taking any medication that
             might pose a risk to the participant or interfere with participation in the study
Clinical trial NCT01068665 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Insulin naïve subject (allowed are: previous short term insulin treatment up to 14
             days; Treatment during hospitalisation or during gestational diabetes is allowed for
             periods longer than 14 days)

          -  Current treatment: metformin monotherapy or metformin in any combination with an
             insulin secretagogue (sulfonylurea or glinide), DPP-4 inhibitor,
             alpha-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months
             prior to visit 1 with the minimum doses stated: -Metformin: alone or in combination
             (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000
             mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the daily
             maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily
             maximal dose according to local labelling - alpha-glucosidase-inhibitors (acarbose):
             minimum half of the daily maximal dose or maximum tolerated dose

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  Body Mass Index (BMI) maximum 45.0 kg/m^2

          -  Type 2 diabetes (diagnosed clinically) for at least 6 months

          -  Ability and willingness to adhere to the protocol including performance of self
             monitored plasma glucose (SMPG) profiles according to the protocol

        Exclusion Criteria:

          -  Use within the last 3 months prior to Visit 1 of: thiazoledinediones (TZDs), exenatide
             or liraglutide

          -  Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements [for UK: adequate contraceptive
             measures are defined as established use of oral, injected or implanted hormonal
             methods of contraception, sterilisation, intrauterine device or intrauterine system,
             or consistent use of barrier methods]

          -  Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous
             cell skin cancer)
Clinical trial NCT00045162 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, etoposide, irinotecan hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed extensive stage small cell lung cancer
             (SCLC)

          -  Measurable or evaluable disease by CT scan, MRI, x-ray, physical exam, or nuclear exam

          -  Brain metastases allowed if previously treated with radiotherapy and/or surgery and
             are neurologically stable (i.e., no progressing symptoms and off steroids and
             anticonvulsants)

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 3,000/mm^3

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST or ALT no greater than 2.5 times ULN

        Renal

          -  Creatinine normal

          -  Creatinine clearance at least 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  HIV negative

          -  No concurrent AIDS-related illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior biologic therapy for SCLC

          -  No filgrastim (G-CSF) within 24 hours of chemotherapy

        Chemotherapy

          -  No prior systemic chemotherapy for SCLC

        Endocrine therapy

          -  See Disease Characteristics

        Radiotherapy

          -  See Disease Characteristics

          -  At least 21 days since prior brain radiotherapy and recovered

          -  No other prior radiotherapy for SCLC

        Surgery

          -  See Disease Characteristics

          -  At least 21 days since prior thoracic or other major surgery and recovered

        Other

          -  No concurrent enzyme inducing antiepileptic drugs (phenytoin, phenobarbital,
             oxcarboxepine, or carbamazepine)
Clinical trial NCT00464061 (phase 3, status: terminated)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: volinanserin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary
    insomnia with predominant sleep maintenance problems
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental
             Disorders (Fourth Edition) criteria

          -  Disturbances of sleep maintenance criteria based on participant's information related
             to sleep pattern during the preceding month

        Sub-study :

          -  Participants will be included if they have an established medical diagnosis of type II
             Diabetes Mellitus, and have been treated either with an oral hypoglycemic agent and/or
             insulin for at least three months prior to the Screening Visit (with stable regimen
             for at least one month prior to screening)

        Exclusion Criteria:

          -  Females who are lactating or who are pregnant

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  Consumption of xanthine-containing beverages (i.e. tea, coffee, cola) comprising more
             than 5 cups/day

          -  Participation in another trial having received study medication within 1 month before
             the screening visit

          -  Body Mass Index ≥ 33

          -  Use of over-the-counter medications such as tryptophan, valerian root, kava,
             melatonin, St. John's Wort, Alluna or prescription sleep medication

          -  Use of any substance with psychotropic effects or properties know to affect sleep/wake

          -  History of primary hypersomnia, narcolepsy, breathing-related sleep disorder,
             circadian rhythm sleep disorder, parasomnia, dyssomnia

          -  Clinically significant, severe or unstable, acute or chronically progressive medical
             or surgical disorder

          -  Positive qualitative urine drug screen (opiates, cocaine, amphetamine…)

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.